Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Paynova in conjunction with raising of capital and change in listing
Mandate

Vinge advises Paynova in conjunction with raising of capital and change in listing

June 07, 2022 Capital Markets and Public M&A

Vinge has advised Paynova AB, under change of name to Sileon AB, in connection with a fully subscribed rights issue valued at approximately SEK 70 million.  

In connection with the issue, Paynova has also made public their intention to implement a change of listing from NGM Regulated to Nasdaq First North Growth Market.

Vinge’s team consisted of, among others, Anders Strid, Edin Agic (project manager), Adrian Filipovic and Amelia Rihs.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024